BioMedNewsBreaks

WednesdayMay 06, 2026 12:35 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Completes $12.5M N2B Asset Transfer to Lunai Bioworks 

Oncotelic Therapeutics (OTCQB: OTLC) announced the consummation of a strategic asset transfer agreement with Lunai Bioworks, Inc., granting worldwide rights to its nose-to-brain (N2B) delivery system IP within biodefense and Alzheimer’s disease fields in exchange for $12.5 million in Series B convertible preferred stock. The agreement establishes an initiative focused on CNS-targeted therapeutics while supporting the company’s strategy to monetize its portfolio and retain control of core assets. The N2B platform enables intranasal delivery directly to the central nervous system, bypassing the blood-brain barrier to support rapid therapeutic action and targeted neurological engagement, with applications in biodefense medical countermeasures and neurodegenerative conditions. Under the agreement, Lunai Bioworks will develop the platform…

Continue Reading

WednesdayMay 06, 2026 12:12 pm

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Reports High Accuracy In Feline Cancer Blood Test Study

VolitionRx Limited (NYSE American: VNRX) announced submission for peer review of a clinical manuscript demonstrating the high accuracy of its Nu.Q Vet Feline prototype assay in detecting lymphoma in cats, achieving 97% specificity and identifying 86% of cases, advancing development of a blood-based liquid biopsy test for feline cancer. The company said the technology addresses a significant unmet need in veterinary medicine and represents a commercial opportunity, with potential milestone payments and future revenue generation, as it works toward product commercialization and expands its presence in the growing companion animal oncology market. The publication of this study in a peer reviewed journal is expected subsequently to unlock a $5…

Continue Reading

TuesdayMay 05, 2026 9:50 am

BioMedNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Initiates First Commercial Manufacturing Order For Preservative-Free Ketamine

NRx Pharmaceuticals (NASDAQ: NRXP) announced it has initiated its first commercial manufacturing order of preservative-free ketamine in anticipation of potential approval under the Generic Drug User Fee Act in summer 2026, supported by stability data from multiple registration batches and a successful third-party manufacturing audit. To view the full press release, visit https://ibn.fm/yEXl3 About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone).…

Continue Reading

MondayMay 04, 2026 10:55 am

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures $22.5 Million Private Placement Financing

CNS Pharmaceuticals (NASDAQ: CNSP) announced it has entered into securities purchase agreements for a private placement expected to generate approximately $22.5 million in gross proceeds, with participation from institutional healthcare investors including ADAR1 Capital, Ikarian Capital, Stonepine Capital Management and Nazare Partners. The company said proceeds will support its strategy to acquire and advance new assets, along with working capital and general corporate purposes, while A.G.P./Alliance Global Partners acted as the sole placement agent for the transaction. To view the full press release, visit https://ibn.fm/usrIh About CNS Pharmaceuticals, Inc. CNS Pharmaceuticals is a biotechnology company focused on developing innovative therapies…

Continue Reading

MondayMay 04, 2026 9:30 am

BioMedNewsBreaks – HealthLynked Corp. (OTCQB: HLYK) Launches Redesigned Platform and Multi-Site Digital Ecosystem

HealthLynked (OTCQB: HLYK) announced the launch of a redesigned consumer platform and multi-site digital ecosystem aimed at improving healthcare access, reducing inefficiencies and enhancing engagement across patients, providers, partners and investors. The company said the new architecture includes dedicated platforms for consumer access, provider engagement, business partnerships and investor relations, supporting its strategy to build a scalable, consumer-driven healthcare platform with national reach and future AI-driven capabilities. To view the full press release, visit https://ibn.fm/cJfsm About HealthLynked Corp. HealthLynked Corp. enhances healthcare through personalized care management that improves outcomes and reduces costs. Its cloud-based platform connects patients with providers for…

Continue Reading

ThursdayApr 30, 2026 1:59 pm

BioMedNewsBreaks — Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Targets Precision Cardiology with Multi-Omic AI Platform

Cardio Diagnostics Holdings (NASDAQ: CDIO) is positioned for opportunity as cardiovascular diagnostics are undergoing a transformation as advances in molecular science and artificial intelligence (“AI”) converge to deliver more precise, individualized insights from minimally invasive tests. The company is “developing a proprietary platform that integrates epigenetic and genetic biomarkers with AI to generate personalized cardiovascular risk assessments from a simple blood sample,” reads a recent article. “At the core of Cardio Diagnostics’ approach is the use of AI to integrate multi-omic data, specifically epigenetic markers such as DNA methylation with genetic information, to provide a more comprehensive view of cardiovascular health. Traditional…

Continue Reading

ThursdayApr 30, 2026 9:50 am

BioMedNewsBreaks – Telomir Pharmaceuticals (NASDAQ: TELO) Receives FDA IND Clearance for Telomir-Zn in Triple-Negative Breast Cancer

Telomir Pharmaceuticals (NASDAQ: TELO), a clinical-stage biotechnology company, announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir-Zn to treat advanced or metastatic triple-negative breast cancer. The clearance enables initiation of a first-in-human Phase 1/2 clinical trial designed to evaluate safety, dosing and preliminary antitumor activity, supported by preclinical pharmacology, toxicology and biomarker data as the Company advances its lead candidate toward clinical development. To view the full press release, visit https://ibn.fm/p4e9J About Telomir Pharmaceuticals Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) is a preclinical-stage biotechnology company developing small-molecule therapeutics designed to target fundamental epigenetic and…

Continue Reading

ThursdayApr 30, 2026 9:30 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances AI and Robotics Platform Toward Initial Commercial Deployment

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biotechnology company, reported continued progress on its proprietary AI platform and robotics integration as it nears initial commercial deployment. The Company has integrated approximately 28 million scientific abstracts into its PDAOAI platform and combined it with robotics developed alongside TechForce Robotics, enabling real-time, automated workflows designed to improve efficiency and support compliance in pharmaceutical development and manufacturing. To view the full press release, visit https://ibn.fm/2uitp About Oncotelic Therapeutics, Inc. Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of oncology and immunotherapy products. The Company’s mission is to address high-unmet-need cancers and…

Continue Reading

ThursdayApr 30, 2026 9:20 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) to Host Q1 2026 Earnings Call and Provide Strategic Updates

HeartBeam (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss first-quarter results ended March 31, 2026, and provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection and AI programs. To view the full press release, visit https://ibn.fm/yN939 About HeartBeam, Inc. HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting…

Continue Reading

WednesdayApr 29, 2026 2:15 pm

BioMedNewsBreaks — Earth Science Tech Inc. (ETST) Leveraging Vertical Integration to Target Precision Medicine Market

Earth Science Tech (OTC: ETST) was featured in a recent article that discussed its efforts to build vertical integration across telemedicine, pharmaceuticals, and clinical services. “At the nucleus of ETST’s model are its compounding pharmacy operations, which produce customized medications tailored for specific patient needs. This segment aims to tackle the growing gap in traditional pharmaceutical manufacturing… Through operating licensed compounding facilities, the company is strategically positioned to serve a niche but quickly evolving market driven by demand for precision treatment and specialized formulations,” reads the publication. “In addition to this, the company’s telemedicine infrastructure operates as a front-end patient acquisition…

Continue Reading